Trials
9 active
13 in total · 11 in the EU
Targets
—
None known yet
What this is
- How it works
- Blocks JAK enzymes that pass on immune signals, to calm an overactive immune system.JAK inhibitor Named by hand
- Tested for
- Ulcerative Colitis
- Main trialPhase 4
- “The primary purpose of this study is to evaluate the efficacy of filgotinib in establishing clinical remission at Week 10 or 22.”In the company’s words, NCT06964113 on ClinicalTrials.gov
- Other names
- Jyseleca
Other drugs for Ulcerative Colitis
- TofacitinibPfizer · Phase 3
- UpadacitinibAbbVie · Phase 3
- RisankizumabAbbVie · Phase 3
- UstekinumabJohnson & Johnson (Janssen) · Phase 3
- IcotrokinraJohnson & Johnson (Janssen) · Phase 3
- ObefazimodAbivax S.A. · Phase 3
Coming up1
- 30 Nov 2027Phase 4 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials13
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Active, not recruiting | 30 Nov 2027 | A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice | |
| Phase 4Completed | 21 Jan 2026 | A Study of Filgotinib in Korean Participants With Rheumatoid Arthritis | |
| Phase 2Not authorised | not given | Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID) | |
| Phase 2Authorised | not given | Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID) | |
| Phase 4Authorised | not given | JAK inhibitor dose TAPering strategy study in low disease activity rheumatoid arthritis patients | |
| Phase 4Ended | not given | PeRsonalIzed MEdicine in Rheumatoid Arthritis (PRIMERA trial): a multicenter, open-label, randomized controlled trial comparing usual care with a tailor-made approach | |
| Phase 3Authorised | not given | FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial | |
| Phase 3/4Authorised | not given | RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASALAZINE + HYDROXYCHLOROQUINE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INSUFFICIENT RESPONSE TO METHOTREXATE OR LEFLUNOMIDE (The BIO-3 trial) | |
| Phase 4Authorised | not given | Filgotinib bridging in newly diagnosed rheumatoid arthritis patients (FAST RA trial); A pragmatic randomized controlled non-inferiority low intervention clinical trial | |
| Phase 4Ended | not given | The effect of Janus Kinase inhibitors on the heart in Rheumatoid Arthrtis | |
| Phase 4Authorised | not given | REDO-JAK: Dose REDuction Of JAnus Kinase inhibitors in patients with inflammatory rheumatic diseases | |
| Phase 4Authorised | not given | Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference | |
| Phase 4Authorised | not given | STOP - Safety and efficacy of a STOPping strategy versus classical maintenance dose of JAK inhibitors in deep remission patients with ulcerative colitis: a randomized controlled trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026